AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
tolnaftate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 3617 | 2398-96-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A synthetic antifungal agent.
|
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AKT2,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK2,MAP3K1,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MARK4,MTOR,NTRK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,TEK,TTK | 44 | |||
| kinase-selectivity-class | AXL,EIF2AK3,ERBB2,GRK2,PDK4,TTK | 6 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Blood uric acid decreased | 33.29 | 24.88 | 6 | 912 | 847 | 90626682 |
| Hypertrophy | 29.62 | 24.88 | 5 | 913 | 483 | 90627046 |
| Hepatosplenomegaly | 25.75 | 24.88 | 6 | 912 | 3003 | 90624526 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Enamel anomaly | 45.83 | 26.22 | 7 | 650 | 234 | 42620444 |
| Tooth hypoplasia | 45.30 | 26.22 | 7 | 650 | 253 | 42620425 |
| Mucormycosis | 39.85 | 26.22 | 11 | 646 | 7132 | 42613546 |
| Tooth disorder | 34.23 | 26.22 | 11 | 646 | 11968 | 42608710 |
| Skin lesion | 32.20 | 26.22 | 13 | 644 | 27161 | 42593517 |
| Bronchopulmonary aspergillosis | 29.03 | 26.22 | 11 | 646 | 19418 | 42601260 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Enamel anomaly | 47.11 | 23.04 | 7 | 1392 | 237 | 110587663 |
| Tooth hypoplasia | 44.44 | 23.04 | 7 | 1392 | 350 | 110587550 |
| Blood uric acid decreased | 28.60 | 23.04 | 6 | 1393 | 1487 | 110586413 |
| Blood creatinine decreased | 26.04 | 23.04 | 8 | 1391 | 9129 | 110578771 |
| Hypertrophy | 25.25 | 23.04 | 5 | 1394 | 930 | 110586970 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | D01AE18 | DERMATOLOGICALS ANTIFUNGALS FOR DERMATOLOGICAL USE ANTIFUNGALS FOR TOPICAL USE Other antifungals for topical use |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000935 | Antifungal Agents |
| CHEBI has role | CHEBI:35441 | antiinfective agent |
| CHEBI has role | CHEBI:50177 | dermatologic drug |
| CHEBI has role | CHEBI:86327 | antifungal drug |
Related Drugs by ATC class:
D01AE Other antifungals for topical use 23 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Tinea capitis | indication | 5441008 | |
| Tinea pedis | indication | 6020002 | DOID:12403 |
| Tinea manus | indication | 48971001 | DOID:13369 |
| Pityriasis versicolor | indication | 56454009 | DOID:9060 |
| Tinea corporis | indication | 84849002 | |
| Tinea cruris | indication | 399029005 | |
| Tinea barbae | indication | 399329002 |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cats | Treatment of ringworm lesions caused by Microsporum canis | Indication |
| Cats | Treatment of ringworm lesions caused by Microsporum gypseum | Indication |
| Dogs | Treatment of ringworm lesions caused by Microsporum canis | Indication |
| Dogs | Treatment of ringworm lesions caused by Microsporum gypseum | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Tinavet Cream 1% | Intervet Inc. | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 2B | GPCR | Ki | 5.89 | DRUG MATRIX | |||||
| Cytochrome P450 2C19 | Enzyme | IC50 | 5.52 | DRUG MATRIX | |||||
| Lanosterol 14-alpha demethylase | Enzyme | IC50 | 4.30 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019415 | VUID |
| N0000147552 | NUI |
| D00381 | KEGG_DRUG |
| 4019415 | VANDF |
| C0040379 | UMLSCUI |
| CHEBI:9620 | CHEBI |
| CHEMBL83668 | ChEMBL_ID |
| DB00525 | DRUGBANK_ID |
| D014047 | MESH_DESCRIPTOR_UI |
| 5510 | PUBCHEM_CID |
| 1730 | INN_ID |
| 06KB629TKV | UNII |
| 10637 | RXNORM |
| 4874 | MMSL |
| 5599 | MMSL |
| 002904 | NDDF |
| 38166006 | SNOMEDCT_US |
| 387204001 | SNOMEDCT_US |
| 06KB629TKV | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Walgreens Athletes Foot | HUMAN OTC DRUG LABEL | 1 | 0363-0155 | AEROSOL, SPRAY | 1 g | TOPICAL | OTC Monograph Drug | 13 sections |
| Tolnaftate | HUMAN OTC DRUG LABEL | 1 | 0363-0216 | AEROSOL, SPRAY | 1.30 g | TOPICAL | OTC Monograph Drug | 14 sections |
| Tolnaftate | HUMAN OTC DRUG LABEL | 1 | 0363-0216 | AEROSOL, SPRAY | 1.30 g | TOPICAL | OTC Monograph Drug | 14 sections |
| Tolnaftate | HUMAN OTC DRUG LABEL | 1 | 0363-1746 | SPRAY | 1.30 g | TOPICAL | OTC Monograph Drug | 14 sections |
| Tolnaftate | HUMAN OTC DRUG LABEL | 1 | 0363-1746 | SPRAY | 1.30 g | TOPICAL | OTC Monograph Drug | 14 sections |
| Maximum Strength Antifungal Liquid | HUMAN OTC DRUG LABEL | 1 | 0363-2026 | LIQUID | 10 mg | TOPICAL | OTC Monograph Drug | 13 sections |
| Maximum Strength Antifungal Liquid | HUMAN OTC DRUG LABEL | 1 | 0363-2026 | LIQUID | 10 mg | TOPICAL | OTC Monograph Drug | 13 sections |
| Antifungal Liquid | HUMAN OTC DRUG LABEL | 1 | 0363-4471 | LIQUID | 10 mg | TOPICAL | OTC Monograph Drug | 13 sections |
| Antifungal Liquid Maximum Strength | HUMAN OTC DRUG LABEL | 1 | 0363-7998 | LIQUID | 10 mg | TOPICAL | OTC Monograph Drug | 13 sections |
| CR-371059 Tolnaftate 1% Cream | HUMAN OTC DRUG LABEL | 1 | 0536-1315 | CREAM | 1 g | TOPICAL | OTC Monograph Drug | 12 sections |
| Athletes Foot | HUMAN OTC DRUG LABEL | 1 | 0536-1481 | AEROSOL, SPRAY | 10 mg | TOPICAL | OTC Monograph Drug | 15 sections |
| Foot Works HealthyAntifungal | HUMAN OTC DRUG LABEL | 1 | 10096-0272 | SPRAY | 10 mg | TOPICAL | OTC monograph final | 13 sections |
| Foot Works HealthyAntifungal | HUMAN OTC DRUG LABEL | 1 | 10096-0303 | POWDER | 10 mg | TOPICAL | OTC monograph final | 12 sections |
| Odor-Eaters Athletes Foot | HUMAN OTC DRUG LABEL | 1 | 10157-3100 | CREAM | 1 g | TOPICAL | OTC monograph drug | 11 sections |
| Blistex Odor-Eaters Powder | HUMAN OTC DRUG LABEL | 1 | 10157-4645 | SPRAY | 1 g | TOPICAL | OTC monograph drug | 12 sections |
| Mentholatum Heel Revival Cream | HUMAN OTC DRUG LABEL | 1 | 10742-0020 | CREAM | 10 mg | TOPICAL | OTC Monograph Drug | 9 sections |
| Lotrimin Daily Prevention Deo | HUMAN OTC DRUG LABEL | 1 | 11523-0010 | AEROSOL, POWDER | 10 mg | TOPICAL | OTC Monograph Drug | 14 sections |
| Lotrimin Daily Prevention | HUMAN OTC DRUG LABEL | 1 | 11523-0011 | POWDER | 10 mg | TOPICAL | OTC Monograph Drug | 14 sections |
| Tinactin | HUMAN OTC DRUG LABEL | 1 | 11523-0072 | AEROSOL, POWDER | 10 mg | TOPICAL | OTC Monograph Drug | 14 sections |
| LotriminDaily Prevent Deodorant | HUMAN OTC DRUG LABEL | 1 | 11523-0136 | AEROSOL, POWDER | 10 mg | TOPICAL | OTC Monograph Drug | 14 sections |
| TinactinDeodorant | HUMAN OTC DRUG LABEL | 1 | 11523-0137 | AEROSOL, POWDER | 10 mg | TOPICAL | OTC Monograph Drug | 14 sections |
| TinactinJock Itch | HUMAN OTC DRUG LABEL | 1 | 11523-0138 | AEROSOL, POWDER | 10 mg | TOPICAL | OTC Monograph Drug | 14 sections |
| Tinactin | HUMAN OTC DRUG LABEL | 1 | 11523-0139 | AEROSOL, POWDER | 10 mg | TOPICAL | OTC Monograph Drug | 13 sections |
| Tinactin | HUMAN OTC DRUG LABEL | 1 | 11523-0165 | AEROSOL, SPRAY | 10 mg | TOPICAL | OTC Monograph Drug | 14 sections |
| Tinactin | HUMAN OTC DRUG LABEL | 1 | 11523-0777 | AEROSOL, POWDER | 10 mg | TOPICAL | OTC Monograph Drug | 13 sections |
| Tinactin | HUMAN OTC DRUG LABEL | 1 | 11523-0934 | CREAM | 10 mg | TOPICAL | OTC Monograph Drug | 14 sections |
| Tinactin | HUMAN OTC DRUG LABEL | 1 | 11523-1190 | CREAM | 10 mg | TOPICAL | OTC Monograph Drug | 14 sections |
| TinactinAntifungal | HUMAN OTC DRUG LABEL | 1 | 11523-4162 | AEROSOL, POWDER | 10 mg | TOPICAL | OTC Monograph Drug | 14 sections |
| Tolnaftate | HUMAN OTC DRUG LABEL | 1 | 11527-051 | CREAM | 10 mg | TOPICAL | OTC Monograph Drug | 10 sections |
| Targetantifungal | HUMAN OTC DRUG LABEL | 1 | 11673-912 | CREAM | 10 mg | TOPICAL | OTC Monograph Drug | 14 sections |